Myeloid checkpoints for cancer immunotherapy

Yixin Qian; Ting Yang; Huan Liang; Mi Deng

doi:10.21147/j.issn.1000-9604.2022.05.07

Myeloid checkpoints for cancer immunotherapy

Chin J Cancer Res. 2022 Oct 30;34(5):460-482. doi: 10.21147/j.issn.1000-9604.2022.05.07.

Authors

Yixin Qian^{1

2}, Ting Yang^{1

2}, Huan Liang², Mi Deng^{1

2

3}

Affiliations

¹ Peking University International Cancer Institute, Health Science Center, Peking University, Beijing 100191, China.
² School of Basic Medical Sciences, Health Science Center, Peking University, Beijing 100191, China.
³ Peking University Cancer Hospital & Institute, Peking University, Beijing 100142, China.

PMID: 36398127
PMCID: PMC9646457
DOI: 10.21147/j.issn.1000-9604.2022.05.07

Abstract

Myeloid checkpoints are receptors on the myeloid cell surface which can mediate inhibitory signals to modulate anti-tumor immune activities. They can either inhibit cellular phagocytosis or suppress T cells and are thus involved in the pathogenesis of various diseases. In the tumor microenvironment, besides killing tumor cells by phagocytosis or activating anti-tumor immunity by tumor antigen presentation, myeloid cells could execute pro-tumor efficacies through myeloid checkpoints by interacting with counter-receptors on other immune cells or cancer cells. In summary, myeloid checkpoints may be promising therapeutic targets for cancer immunotherapy.

Keywords: Cancer; MDSC; TAM; immune checkpoint; immunotherapy; myeloid checkpoint.